Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jee H Choe

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Blood Advances|December 28, 2023
Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphomaJee H Choe, Tianzhou Yu, Jeremy S Abramson, et al.
JAMA Network Open|December 15, 2022
Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell LymphomaJee H Choe, Hisham Abdel-Azim, William V Padula, et al.
The American Journal of Managed Care|April 11, 2024
Medication persistence and its impact on type 2 diabetesJee H Choe, Si Xuan, Antony Goldenberg, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Blood Advances|December 28, 2023
Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphomaJee H Choe, Tianzhou Yu, Jeremy S Abramson, et al.
JAMA Network Open|December 15, 2022
Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell LymphomaJee H Choe, Hisham Abdel-Azim, William V Padula, et al.
The American Journal of Managed Care|April 11, 2024
Medication persistence and its impact on type 2 diabetesJee H Choe, Si Xuan, Antony Goldenberg, et al.
Pageof 1